Compare TIL & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIL | XTNT |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 82.6M |
| IPO Year | 2021 | N/A |
| Metric | TIL | XTNT |
|---|---|---|
| Price | $11.40 | $0.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $100.67 | $1.50 |
| AVG Volume (30 Days) | 62.3K | ★ 231.4K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $133,083,000.00 |
| Revenue This Year | N/A | $15.95 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $68.87 |
| Revenue Growth | N/A | ★ 16.88 |
| 52 Week Low | $10.69 | $0.34 |
| 52 Week High | $42.79 | $0.95 |
| Indicator | TIL | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 63.71 |
| Support Level | $10.72 | $0.70 |
| Resistance Level | $11.85 | $0.81 |
| Average True Range (ATR) | 0.60 | 0.06 |
| MACD | 0.25 | 0.02 |
| Stochastic Oscillator | 60.52 | 81.42 |
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.